Genmab/$GMAB
1D1W1MYTD1Y5YMAX
Capital at risk
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Ticker
- $GMAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,119
- Headquarters
- Copenhagen, Denmark
- Website
- www.genmab.com
Genmab Metrics
BasicAdvanced
$19B
2.55
$12.65
0.69
-
Price and volume
Market cap
$19B
Beta
0.69
52-week high
$35.43
52-week low
$23.62
Average daily volume
2.5M
Financial strength
Current ratio
2.457
Quick ratio
2.441
Long term debt to equity
83.28
Total debt to equity
88.518
Interest coverage (TTM)
4.96%
Profitability
EBITDA (TTM)
1,377
Gross margin (TTM)
93.03%
Net profit margin (TTM)
19.08%
Operating margin (TTM)
32.29%
Effective tax rate (TTM)
13.02%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
8.79%
Return on equity (TTM)
14.00%
Valuation
Price to earnings (TTM)
2.548
Price to revenue (TTM)
0.481
Price to book
20.88
Price to tangible book (TTM)
-38.03
Price to free cash flow (TTM)
2.287
Free cash flow yield (TTM)
43.72%
Free cash flow per share (TTM)
14.091
Growth
Revenue change (TTM)
22.26%
Earnings per share change (TTM)
-36.79%
3-year revenue growth (CAGR)
18.55%
10-year revenue growth (CAGR)
34.68%
3-year earnings per share growth (CAGR)
5.57%
10-year earnings per share growth (CAGR)
22.19%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Analyst projections of the future price of Genmab stock.
Bulls say / Bears say
Genmab reported Q2 2026 Darzalex net trade sales of $4.207 billion, underscoring its robust royalty income stream. (Stockopedia)
First-half 2026 Darzalex net sales by J&J totalled $8.17 billion, a 21% year-over-year increase, reinforcing the strength of Genmab’s flagship product. (Stockopedia)
Genmab raised full-year 2026 revenue guidance to $4.325–$4.525 billion and adjusted operating profit guidance to $1.07–$1.39 billion, signaling confidence in its growth trajectory. (Stockopedia)
The Phase 3 trial of epcoritamab failed to reach statistical significance, casting doubt on the future potential of this key pipeline candidate. (TradingView)
Overreliance on Darzalex royalties leaves Genmab vulnerable to competitive and patent expiry risks, with Darzalex net sales growth of 21% in H1 2026 potentially slowing post-exclusivity. (Stockopedia)
The $8.0 billion Merus acquisition, though expected to be accretive by 2029, creates near-term dilution and heightens execution risk over a multi-year integration horizon. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Upcoming events
No upcoming events
Genmab News
AllArticlesVideos
Genmab A/S Q2 Earnings Call Highlights
MarketBeat1 month ago
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Business Wire2 months ago
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Benzinga2 months ago
Funds containing Genmab
AllUSDGBP
Fund name | Fund size | $GMAB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.15% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.